Impact of genetic changes on SCLC subtypes and treatment response
Official title: Impact of recurrent genetic alterations on SCLC subtypes and therapeutic response
Funded at New York University School of Medicine · NIH-11390989 · Data updated 2026-11-12
This project explores how specific genetic changes in small cell lung cancer (SCLC) affect the disease and how it responds to targeted drugs.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 16, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $351,713 |
| NIH project number | 5P01CA288368-03 |
| Project ID | NIH-11390989 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose tumors carry the mutations studied (e.g., P53 and RB1 with co-mutations like MYC, KMT2D, STK11/PTEN) and who may receive future targeted therapies or immunotherapies.
✕Less likely to help
Patients whose tumor genetics do not match the studied co-mutation patterns may not benefit from these specific strategies.
What this research studies
Researchers at NYU Langone will study SCLC by creating animal and cell models that carry common patient mutations. They will test how co-mutations like MYC, KMT2D, STK11/PTEN and others influence replication stress and tumor growth, and whether CDK2 or PARP inhibitors work better in these contexts. The study also aims to separate tumor-intrinsic effects from immune system interactions using immune-competent models, and to evaluate combinations of targeted drugs with immunotherapy. Findings could guide more precise treatment strategies for different SCLC subtypes.
Why it matters
Potential benefit: If successful, the research could identify which genetic profiles predict better responses to specific therapies and inform more personalized SCLC treatments.
How similar studies have gone: Similar studies in cancer biology have shown that genetic context can alter treatment response, but this exact combination in SCLC is being explored.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Wong, Kwok Kin — New York University School of Medicine
- Study coordinator: Wong, Kwok Kin
Related research
Other NIH-funded projects on the same topics.
-
Role of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC in the Immunotherapy Era
This project looks at whether giving twice-daily radiotherapy for limited-stage small cell lung cancer still helps patients today who are also getting immunotherapy.
-
SCLC model creation and therapy testing
A cancer research program using mouse models and engineered human and mouse cells to study small cell lung cancer and test potential treatments.
-
Repair mechanisms for DNA lesions in small cell lung cancer
Researchers are studying how cancer cells with small cell lung cancer respond or become resistant to treatment by looking at the ways DNA damage is repaired.
-
Understanding how replication stress affects a hard-to-treat breast cancer gene patients may carry
This grant explores how certain breast cancer gene defects interact with replication stress to influence cancer cell survival and treatment resistance, with potential implications for therapies in patients with BRCA2-related breast cancer.
-
Replication Stress Sensing Defects in Small Cell Lung Cancer
A study in people might not be involved directly, but it aims to understand why a common lung cancer responds poorly to therapy over time by examining how cancer cells handle replication stress.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.